-
Orthopedic Research and Reviews
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Rational use of nonsteroidal anti-inflammatory drugs and proton pump inhibitors in combination for rheumatic diseases
Review
(1937) Views (631) Full article downloads
Authors: Wolfgang W Bolten
Published Date September 2010
Volume 2010:2 Pages 75 - 84
DOI: http://dx.doi.org/10.2147/ORR.S7324
Wolfgang W BoltenDivision of Rheumatology, Klaus-Miehlke Klinik, Wiesbaden, Germany
Abstract: Nonsteroidal anti-inflammatory drugs (NSAIDs) are successfully used to alleviate pain and inflammation in rheumatic diseases. In an appreciable percentage of cases, the use of systemic NSAIDs is associated with adverse lesions of the gastrointestinal (GI) mucosa up to life-threatening perforations, ulcers, and bleeding. Reliable warning signals mostly do not arise. Therefore, it is important to take preventive measures to reduce the GI risk. One established method is to assign cyclooxygenase 2 (COX-2)-specific inhibitors (coxibs) instead of traditional NSAIDs (tNSAIDs). Coxibs spare in part the endogenous gastroprotective mechanisms. Another reliable choice to improve the GI safety is the comedication of proton pump inhibitors (PPIs) to suppress gastric acid. A fixed NSAID/PPI combination ensures expected protective effects by improving patients’ PPI adherence and physicians’ PPI prescription persistence. A fixed combination of enteric-coated naproxen and immediate-release esomeprazole has just been approved by the US Food and Drug Administration. PPI combinations with aspirin, other tNSAIDs, and coxibs are desirable. Patients in all risk groups, even patients at low risk of GI adverse events, benefit from concomitant protective measures. Moreover, the literature suggests that NSAID/PPI combinations are cost effective, including for patients in low-GI-risk groups. Pricing of fixed NSAID/PPI combinations will play a pivotal role for their broad acceptance in the future.
Keywords: PPI, NSAID, fixed combination, gastrointestinal, adverse events, prevention
Readers of this article also read:
Bisphosphonate-induced femoral fragility fractures: What do we know?
Update on the management of Dupuytren’s contracture
Role of cartilage-forming cells in regenerative medicine for cartilage repair
Treatment of osteoarthritis knee pain: update on use of intra-articular hylan G-F 20
Topical diclofenac in the treatment of osteoarthritis of the knee
Erratum
Perspectives on the clinical utility of allografts for bone regeneration within osseous defects: a narrative review
Subclinical infection associated with delayed union after transtrochanteric rotational osteotomy
Wear of knee prostheses
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- Local anesthetic failure associated with inflammation: verification of the acidosis mechanism and the hypothetic participation of inflammatory peroxynitrite
- Inflammatory mediators: Parallels between cancer biology and stem cell therapy
- Inflammatory mechanisms in the lung
- Rotator cuff troublemakers: pitfalls of MRI and ultrasound




